ADARx

Recent news mentioning ADARx

• 2026-10-01 — ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
• 2026-09-24 — ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
• 2026-09-21 — Drug developer ADARx seeks $1.74 billion valuation in US IPO

Appears alongside

• US IPO

Browse the full archive →